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The aim of this review was to identify empirically supported barriers and facilitators for 
prescribing opioids for Chronic Non-Cancer Pain (CNCP) through a systematic review of 
qualitative literature. Six databases were searched from inception to June 3, 2019 for qualitative 
studies reporting on provider knowledge, attitudes, beliefs, or practices pertaining to prescribing 
opioids for CNCP in North America. Data were extracted, risk of bias rated, and confidence in 
evidence graded using Cochrane Confidence in the Evidence from Reviews of Qualitative 
research (CERQual). Constructs identified were coded using the Theoretical Domains 
Framework. Twenty-six studies reporting on 599 healthcare providers were included. Fourteen 
constructs were identified as barriers or facilitators to prescribing opioids for CNCP that fell 
within seven domains. Domains and constructs identified as barriers included: (1) Environmental 
Context, (a) patient-related salient events (e.g., overdose), (b) provider-related salient events 
(e.g., threat by patient), and (c) time constraints; (2) Emotion, (a) concerns over problematic use, 
addiction, dependence, tolerance, and side effects, and (b) regulatory scrutiny; (3) Knowledge; 
(4) Beliefs About Consequences; and (5) Beliefs About Capabilities. Domains and constructs 
identified as facilitators included: (1) Environmental Context, (a) lack of available non-opioid 
alternatives, and (b) institutional pressure; (2) Social Influences, (a) patient-provider relationship, 
and (b) patient-provider communication; (3) Goals; and (4) Knowledge on opioid prescribing 
tools. Understanding the barriers and facilitators that influence opioid-prescribing offers 
important insight into modifiable targets for interventions that can support providers in 
delivering care consistent with guidelines to manage CNCP, while minimizing risks. 
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Healthcare provider knowledge, beliefs and attitudes regarding opioids for chronic non-
cancer pain in North America: A systematic review 
Chronic Non-Cancer Pain 
Chronic non-cancer pain (CNCP) is defined as pain that persists beyond three months or 
the typical duration of healing,1 and is considered one of the most prevalent, debilitating and 
complex medical conditions to manage. 2 The World Health Organization (WHO) incorporated 
chronic pain as a chronic disease in May of 2019 in the International Classification of Diseases 
(ICD-11). 3,4 While estimates vary depending on survey methodology, nationally representative 
data from Canada, the United States, Germany, and other European countries indicate that 20% 
to 30% of adults suffer from CNCP. 5-9 Chronic pain affects approximately one in every five 
Canadians, or about 6 million Canadians of all ages.9 A national survey reported that more than 
50% of those affected report having experienced moderate to severe pain for more than 10 
years.9 The prevalence of chronic pain is highest among women, older adults, ethnic minorities, 
and Indigenous peoples.3,9-11 Chronic pain confers a significant burden on an individual’s 
activities of daily living, family life, and employment, which can consequently increase 
psychological distress and reduce quality of life. 5,10,12  
Opioids to Improve Pain Management  
The primary goal for pain management is to reduce pain and improve overall functioning 
and quality of life for people with CNCP.13 Given the demonstrated effectiveness of opioids for 
moderate to severe acute pain, and for people with cancer-related pain,14 opioid analgesics have 
been commonly prescribed to treat CNCP.15,16 A low-quality evidenced paper from 1986 initially 
reported that long-term opioid prescribing can be used safely for pain management with few 
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adverse effects.17 This paper was widely cited, leading to the inflation of prescription opioids to 
manage pain.18 
Commonly prescribed opioids include codeine, fentanyl, hydromorphone, hydrocodone, 
methadone, morphine, oxycodone, and tramadol.19 Canada is one of the largest consumer of 
opioids per capita worldwide when measured by defined daily doses, only second to the United 
States.20 Observational studies reported a four-fold increase in the sale of prescription opioids,21 
five-fold increase in drug treatment admissions for prescription opioids (from ~20,000 to 
~120,000),22 two-fold increase in emergency department visits related to pharmaceutical 
opioids,23 and four-fold increase in opioid-related overdose between 1997 and 2011.24 While 
prescribing rates have evidenced a slight decline since 2011,25 the prevalence of exposure to 
opioids has remained high with an estimated 226 million defined daily doses (6,246 per 1,000 
population) of prescription opioids dispensed in Canada in 2016.15 This significant increase of 
opioid prescribing has inevitably contributed to the opioid crisis across North America.15,16 
Efficacy of Opioids for Management of Chronic Pain 
 While commonly prescribed, evidence for the benefits of opioid analgesics for the 
management of CNCP is modest (risk difference [RD] of achieving the minimally important 
difference [MID] in pain relief, versus placebo, is 12%).26 Researchers suggest that there is no 
benefit to using opioids over nonopioid treatments when improving pain-related function and 
quality of life. 27,28Additionally, guidelines report limited evidence suggesting benefit in 
prescribing long-term opioid use for the management of pain.29 It is estimated that 8 and 12 
patients would need to be treated with opioids, relative to placebo, for only one to experience 
improved pain control and function, respectively.26  
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Adverse Effects of Opioids 
Adverse effects of long-term use of opioid therapy range from low- to high-risk life 
threatening events. Lower-risk side effects include constipation, vomiting, nausea, sedation, 
dizziness, drowsiness, pruritis, and dry mouth.26 Prolonged use of opioids can induce higher-risk 
side effects that can impact a variety of organ systems within the body. These include respiratory 
(e.g., increased chance of sleep disordered breathing), musculoskeletal (e.g., osteoporosis and 
increased risk of fractures), cardiovascular (e.g., higher risk of myocardial infarction or heart 
failure), immune, and endocrine systems.30  
In addition to serious health risks, long term opioid use can result in opioid misuse, 
dependence, opioid use disorder, accidental overdose, and death.21 31 Research indicates that 
there is a positive correlation between increased prescribing rates of opioids and misuse, 
emergency room visits, overdose, and death.32 An estimated 92% of people who experience 
problematic opioid use started by taking prescription opioids,33 and three out of four individuals 
who use heroin report that their misuse of narcotics began with prescription opioids.34 
Hospitalization visits have increased over 30% from 2007 to 2014 due to opioid poisoning with 
over 13 hospitalization visits per day in 2014 compared to 9 visits per day in 2007 in Canada.35 
Deaths attributable to opioids are responsible for 58% of drug-related deaths in Ontario – one of 
the most populated provinces in Canada.36 Death rates in this province have reached nearly 3,000 
individuals (8.1 per 100 000 population),37 with one in every 133 deaths attributable to opioids.38 
Nationally, the opioid-related mortality rate in 2016 was 7.9 per 100,000 population, with one in 
every 91 deaths being attributed to opioids.39  
Results from a systematic review found that the co-morbidity of substance use disorder 
(SUD) and CNCP was broad, ranging from 3% - 48%,40 with highest rates of SUD found in 
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individuals with recurrent visits to the emergency room seeking opioid refills.41 Problematic 
opioid use is reported in 10% of patients with CNCP, and 5.5% of patients prescribed opioids for 
CNCP meet criteria for an opioid use disorder.42 An evidence-based review reported that 3.3% 
individuals with CNCP became addicted to opioids, and 11.5% reported partaking in opioid 
misuse, such as drug hoarding.43 A more recent systematic review reported that the prevalence of 
co-morbid SUD and CNCP was found to be as high as 59.9% compared to individuals who had 
CNCP without SUD (44.9%). Among the individuals diagnosed with co-morbid CNCP and 
SUD, opioid use disorder was the most commonly diagnosed SUD (74.7%).44 Individuals who 
have co-morbid SUD and CNCP are also more likely to be prescribed opioids than those without 
a history of SUD40 and are more likely to experience opioid misuse.45 
Diversion  
In addition to side effects associated with opioid use, individuals will often engage in 
aberrant drug-related behaviours, including diversion. Drug diversion is defined as the unlawful 
channelling of regulated pharmaceuticals from legal sources to the illicit marketplace (e.g., 
selling prescribed opioids).28 Diversion of opioids has been known to occur at any point during 
manufacturing and distribution phases. For example, opioids can be diverted through theft at 
plants or in transit to a pharmacy during the preclinical phase or through theft, selling, or sharing 
drugs during the post clinical phase.46 Diversion has also been identified through double 
doctoring, prescription fraud/forgery, street markets, thefts and robberies, and online purchasing. 
28,47 Prescription drug diversion is estimated to be a $25 billion/year industry according to the 
Drug Enforcement Administration of Canada.48 Results from a systematic review and meta-
analysis reported that prescription drugs are primarily sourced through friends and family with 
active opioid prescriptions (57% of cases of diversion), with a smaller proportion being diverted 
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from legitimate medical sources, such as obtaining an excess supply of prescribed opioids (29% 
of cases of diversion).47 In line with the increase of opioid prescribing rates from 1997 to 2011, 
rates of diversion have also significantly increased from 2002 to 2010, and plateaued between 
2011 and 2013.49  
Provider Attitudes Towards Opioid Prescribing 
There is contradicting evidence towards provider confidence for prescribing opioids and 
their willingness to prescribe opioids to people with CNCP. Results from surveys suggest that a 
number of providers are confident in their ability to prescribe opioids,50-52 however, as many as 
82% of providers report reluctance to prescribe opioids, and in some cases, are not willing to 
prescribe opioids even as a third line therapy.53-55  
Clinical practice guidelines have been established to assist providers with the 
management of opioid prescribing for people with CNCP,29,56 however, results from a meta-
analysis report that almost 40% of providers do not follow these recommendations.57 Given the 
trade-off between risks and benefits, healthcare providers express understandable uncertainty 
regarding whether, when, and how to prescribe opioid analgesics for the management of CNCP. 
Other factors that contribute to provider uncertainty and discomfort to manage CNCP include 
inadequate level of education, concerns about patient harms associated with opioids use, 
cognitive biases, and regulatory scrutiny.  
Education  
Education is a common factor that is associated with provider confidence and 
preparedness to prescribe opioids for people with CNCP. Providers who felt that they received 
an adequate amount of training or education for the management of CNCP were more willing 
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and more likely to prescribe opioids to patients.58 However, many providers strongly disagree 
with the statement that they received an adequate education surrounding treatment of CNCP 
during formal education.59,60 For example, as many as 54% and 81% of physicians surveyed 
reported that they received insufficient education about chronic pain management during 
residency and medical school, respectively,61 and only 17% of physicians reported receiving any 
specialty education on pain management.62 Canadian medical undergraduate education programs 
offered an average of 16-hours on pain management in 2007.63 Further, a 2011 review of medical 
curricula across North America indicated that despite advances in pain science, the amount of 
pain education for students is limited, variable, or fragmented.64 These reviews reflect physician 
responses to perceived inadequate amount of education, and consequently impacts physicians 
concern and preparedness towards pain management.  
Familiarity of guidelines may also impact provider confidence in prescribing opioids. 
Despite numerous publications of guidelines to help providers effectively care for patients with 
CNCP,29,56,65-67 providers report that they are not sufficiently familiar with guidelines. Being 
aware of clinical practice guidelines is an integral component in pain management, as those who 
are familiar with guidelines are less likely to believe opioids are effective, have greater concerns 
surrounding opioid dependence, are more likely to screen their patients for depression and 
substance abuse, and have greater confidence in caring for patients with CNCP.54 Approximately 
41% of health care providers across five studies reported low levels of familiarity of guidelines, 
or recalled reading the guidelines but did not remember the content.54,68-71 Being unfamiliar with 
guidelines may lead to greater provider reluctance and uncertainty towards prescribing opioids 
for patients with CNCP.  
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Concerns About Patient Harms With Opioid Use  
Evidence from surveys indicate that providers believe opioids are effective in improving 
pain management.51,53,62,72-75 Nevertheless, given the varied range of the prevalence of opioid 
misuse and problematic opioid use disorder, 40,41,43,44 providers often report an understandable 
level of concern, discomfort, and frustration over problematic opioid use and will often report 
these concerns as a barrier to prescribing opioids.72  
Between 23% and 84% of providers believe that patients are at risk of abuse, dependence, 
or addiction if prescribed opioids, and fear that their prescriptions may contribute to one or all of 
these three. 54,61,68,76,77 The majority of these providers indicate that the potential for addiction 
acts as a barrier to prescribing opioids to these patients.61 Additionally, 16% and 42% of 
providers mention that they would not prescribe opioids to a patient who has previously or 
currently abuses substances, respectively.71 Other side effects, including cognitive impairment, 
drowsiness, and physical effects additionally contribute to provider’s reluctance to prescribe 
opioids, with more than two thirds of providers reporting concerns that these side effects will 
adversely affect their patients. 53,61,75,76,78 
Given the increase of societal diversion,47,49 providers are hesitant to prescribe opioids for 
their patients, in fear that they will contribute to opioid diversion within the community. 50,60-
62,68,75 Providers have stressed the importance on learning about evaluating and managing the 
risks of diversion, in addition to abuse, misuse, dependence, and tolerance amongst individuals 





Cognitive biases, or heuristics, are unconscious mental shortcuts that have been found to 
skew medical judgements and impact clinical decision making.79 A critical review identified 19 
different heuristics that have impacted clinical decision making, including the availability and 
representative heuristics, two of the most common heuristics seen in medical practice.80 
Availability heuristic. Availability heuristics occur when the perceived probability of an 
event is influenced by the ease to which an instance or occurrence can be brought to mind.81 
Often, events more easily recalled are due to the salient emotion attached to the event or 
memory. Providers will often use these past salient memories to help make their current decision, 
subsequently impacting present provider decision making.81 For example, a previous study 
reported that physicians whose patients experienced adverse events (e.g., hemorrhaging) after 
being prescribed warfarin medication were 21% less likely to prescribe the same medication for 
future patients than physicians whose patients did not experience adverse events.82 These 
previous events were easily recalled as they were salient adverse events, and subsequently 
impacted their current prescribing behaviours and decisions. Conversely, physician’s inability to 
recall negative outcomes reinforced their current prescribing behaviours, such that those who do 
not recall previous adverse events will not change their prescribing strategies.83 In the context of 
opioid prescribing, physicians may become hesitant to prescribe opioids to current patients if 
they recall a salient memory of a previous patient experiencing adverse events when taking 
opioids, such as overdose or death.  
Representativeness heuristic. This heuristic represents the judgement of a present 
situation based off the similarities to a category or a mental prototype.81 This could include the 
degree to which the characteristics of a given sample is representative of the characteristics of a 
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specific category.79 For example, health care providers can assess the symptoms and 
characteristics of an individual, and if these characteristics are representative of a specific 
diagnostic criteria, providers will often make the diagnosis. 80 
In some cases, providers will base the sample off a population. For example, they will 
evaluate how much a presenting case’s situation is representative a previous group of patients 
who have demonstrated similar symptoms or patterns.84 Specifically, in a qualitative study 
evaluating the representative heuristic in provider decision-making, one provider quoted “You 
remember past experiences of similar patients with similar conditions… You know what you’re 
looking at.”83 Provider’s confidence in the diagnostic prediction can arise from the strength of 
the similarity between the sample and the population, thus becoming more likely to diagnose the 
presenting individual with the same diagnosis as the previous population’s diagnosis.84 In the 
context of opioid prescribing, providers may be more quickly to diagnose a patient who has 
CNCP with the diagnosis of substance use disorder if they present similar characteristics to a 
previous group of patients that have been diagnosed with CNCP and substance use disorder, 
which can subsequently impact prescribing decision-making.  
Regulatory Scrutiny  
Given the increase of opioid prescribing regulations and media coverage on the opioid 
epidemic, providers express concern about the potential of regulatory scrutiny when prescribing 
opioids, especially stronger acting (schedule II) opioids.53,55,71,74,78,85-87 Despite the support for 
the appropriate prescriptions of stronger acting opioids for people with CNCP,88,89 providers 
express fear of legal investigation, legal action or punishment, or sanctioning by the state 
medical board due to the prescribing, resulting in a reluctance or restricting of opioid prescribing 
for their patients.53,78,90 In order to avoid investigation, some providers will limit the number of 
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refills prescribed, prescribe opioids in a lower schedule, quantity, or dose, or abruptly cease the 
prescription of opioids for their patients, all of which can result in patients receiving 
unfavourable or neglected treatment for their pain.55,86  
Rationale for the Current Knowledge Synthesis 
It is evident that there are significant provider concerns regarding the prescription of 
opioids to patients with CNCP that can impact the level of care given to patients. Toye and 
colleagues91 have qualitatively synthesized provider’s experiences of prescribing opioids for 
CNCP but did not focus on barriers or facilitators. The purpose of this knowledge synthesis was 
to identify empirically supported barriers and facilitators for prescribing opioids for CNCP 
(without judgment to the appropriateness of prescribing practices) through a systematic review of 
qualitative literature. We used a qualitative synthesis to compare the themes across studies in 
order to gain an in depth understanding of provider’s perceptions regarding barriers and 
facilitators of prescribing opioids for CNCP. The identification and understanding of factors that 
influence provider prescription of opioids for the management of CNCP may highlight targets 
for improving the development and delivery of initiatives to improve the alignment between 
evidence-based guidelines and practice.  
Method 
Data Sources and Search Strategy 
A detailed description of data sources and search strategies can be located in the 
published protocol (PROSPERO registration# CRD42018091640).92 In brief, a search strategy 
was developed by an experienced information specialist in consultation with content experts 
from the review team and subject to peer review by an independent information specialist prior 
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to execution. A systematic search was performed from inception to June 3, 2019 using five 
electronic databases: CINAHL, Embase, MEDLINE, PsycINFO, and Cochrane CENTRAL. We 
searched the Cochrane library databases and the Joanna Briggs Institute for relevant systematic 
reviews and PROSPERO for relevant registered protocols. Manual searches of the reference lists 
of relevant systematic reviews were performed to identify additional eligible studies.  
Inclusion Criteria 
Studies were eligible if they met the following criteria: 1) qualitative in design; 2) 
included healthcare providers with privileges to prescribe opioids; 3) explored attitudes, beliefs 
or behaviours; 4) focused on the prescription of opioids for CNCP; and 5) were conducted in 
North America. We focused on North America because opioid-related prescribing practices, non-
medical use and harms are greatest in this area of the world.93  
Exclusion Criteria 
Studies were excluded if the primary focus pertained to the management of problematic 
opioid use. Conference abstracts and review articles were excluded. 
Screening and Data Extraction 
Two teams of research assistants worked in pairs to independently screen titles and 
abstracts for eligibility, and full-text publications of all potentially relevant articles. The 
reference management software Rayyan94 was used to remove any additional duplicates and to 
sort articles based on inclusion and exclusion criteria. Disagreements on inclusion and exclusion 
of articles between reviewers were resolved by consensus or arbitration if necessary. Inter-rater 
agreement was quantified using Cohen’s Kappa and percentage (%) agreement. 
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The same four reviewers used a standardized data extraction tool to extract data from 
eligible studies, such that two reviewers independently extracted data from each study. Data 
were extracted that pertained to: 1) study methodology; 2) prescriber characteristics; 3) patient 
characteristics; 4) measures used; 5) methodological characteristics that informed the assessment 
of risk of bias; and 6) results. 
Risk of Bias and Quality Assessment 
 Risk of bias of included studies was assessed independently and in duplicate using the 
10-item Critical Appraisal Skills Programme (CASP95) quality assessment tool. The CASP tool 
is the most commonly used tool in qualitative evidence syntheses in Cochrane and the World 
Health Organization (WHO) guideline development processes.96 This tool identifies three 
sections of issues encompassing the 10 quality assessment items that need to be considered when 
evaluating a critical study: Issue A: Are the results of the study valid? Questions pertaining to 
issue A include: 1) Was there a clear statement of the aims of the research? 2) Is a qualitative 
methodology appropriate? 3) Was the research design appropriate to address the aims of the 
research? 4) Was the recruitment strategy appropriate to the aims of the research? 5) Was the 
data collected in a way that addressed the research issue? and 6) Has the relationships between 
researcher and participants been adequately considered? Issue B: What are the results? Questions 
pertaining to issue B include: 7): Have ethical issues been taken into consideration? 8) Was the 
data analysis sufficiently rigorous? and 9) Is there a clear statement of findings? Issue C: Will the 





Approach to Evidence Synthesis 
Synthesis of data from qualitative studies was conducted using a thematic analysis 
approach.97 In brief, two investigators independently coded text of all eligible studies to develop 
descriptive themes. Meetings were held to review descriptive themes and generate analytical 
themes until saturation of themes were reached. Previous research has argued that the synthesis 
of qualitative research may not be trustworthy, as it challenges the integrity of contributing 
primary studies, and concepts found in one article may not contribute to others. 98,99 In line with 
primary qualitative research, synthesizing qualitative research is required to have a sophisticated 
process of analysis and interpretation. That is, review authors are encouraged to be sensitive to 
the importance of context and to examine possible theoretical contributions when synthesizing 
research.100 By maintaining this, synthesizing qualitative research does not depend on subjective 
interpretation but rather a subtle realist position, allowing qualitative research synthesis to be 
considered trustworthy.100   
Analytical themes were coded according to the Theoretical Domains Framework 
(TDF)101 to code barriers and facilitators for prescribing opioids to manage CNCP. Originally 
developed to understand health professional behaviour, the TDF distills 33 theories of behaviour 
change into 14 domains that provide a theoretical lens through which to view cognitive, 
affective, social, and environmental influences on behaviour.101 Healthcare provider statements 
about barriers and facilitators were assigned to a relevant TDF domain or set of domains using a 
process described by Cane et al.102 Selection of the most appropriate domain(s) was based on the 
topic and context of statement underlying qualitative themes. Two reviewers independently 
categorized barriers and facilitators. Discrepancies were resolved through consensus. 
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Assessing Confidence in Evidence 
As recommended by the Cochrane Qualitative and Implementation Methods Group,96 
confidence in themes pertaining to healthcare provider facilitators and barriers to the prescription 
of opioid analgesics to manage CNCP was assessed in accordance with the Grading of 
Recommendation, Assessment, Development, and Evaluation-Confidence in the Evidence from 
Qualitative Reviews (GRADE-CERQual) approach.103 Four components are considered when 
grading evidence using the CERQual approach: 1) risk of bias; 2) relevance of the contributing 
study’s aims and content to the overall review question; 3) coherence and consistency of results 
across included studies; and 4) quantity of data supporting a review result. Confidence ratings 
started at “high” and were downgraded by one or more levels if there were concerns regarding 
individual CERQual components. 
Results 
Identification of Studies 
We identified 12,253 citations and reviewed 383 full-text articles. Inter-rater agreement 
was substantial at the title/abstract stage, k = 0.92 (95.98%), and moderate at the full-inclusion 
stage, k = 0.62 (80.78%). Twenty-seven qualitative studies104-130 met inclusion criteria. Two 
studies reported on the same data129,130 resulting in 26 unique studies, refer to Figure 1. 
Study Characteristics 
Eligible studies enrolled 599 healthcare providers (487 primary care providers, 19 
specialist physicians, 35 nurse practitioners, 27 pharmacists, 13 physician assistants, 12 medical 
residents, and six reported as “other”; refer to Table 1). In general, risk of bias among eligible 
qualitative studies was low (Table 2). The CASP criterion least commonly met was “has the 
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relationship between researcher and participant been adequately considered?” Table 3 depicts a 
summary of review themes and level of confidence that themes extracted reflect the true state of 
affairs. 
Barriers to Opioid Prescribing 
Knowledge of Opioid Prescribing and Pain Management  
Seven studies108,114,117,118,121,125,126 assessed healthcare provider perceived adequacy of 
formal education surrounding the prescription of opioid analgesics for the management of 
CNCP. A sample of 140 healthcare providers (108 primary care, 7 specialist physicians and 25 
pharmacists) indicated that perceived inadequate education on the prescription of opioids for 
pain management received during formal education was a barrier to prescribing opioids 
(moderate confidence). Some providers took the initiative to seek additional training on their 
own volition.  
“I didn’t learn [information on pain management] in school, that is for sure. We took an 
advanced pharm class, and we discussed [pain management] in one lecture, but that was 
it. Isn’t that ridiculous considering how many people we see in pain?”114  
“I’ve basically sought out my own training because it was not something that was taught 
to me in medical school or residency.” 117 
Beliefs About Capabilities  
Nine studies104,106,111,118-123 assessed healthcare provider self-efficacy when prescribing 
opioid analgesics to manage patients with CNCP. The sample consisted of 194 providers (176 
primary care, 9 specialist physicians, 7 nurse practitioners, 1 physician assistant, and 1 other). 
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Most healthcare providers reported low confidence in their abilities to prescribe opioids to 
manage patients with complex CNCP cases (moderate confidence).  
“It’s awful, and I think it’s demoralizing when you leave people in pain. That’s just so 
disrespectful. I mean you’re supposed to be a doctor, you’re supposed to relieve pain and 
suffering, and you ignore the pain.” 104 
“[I am uncomfortable treating] people that you classify with chronic pain syndrome... In 
my experience, it is a black hole.”106 
“It can be a tough call sometimes. When I do prescribe, I’m a little bit uneasy.” 123 
Some providers did not feel confident in their abilities to manage pain for patients with a 
previous or current history of substance use.  
“Nobody here knows how to treat pain in anybody who has a history [of addiction] and 
already on something like methadone… nobody knows how to treat them… It’s a 
mistake… promoting doctors like me to [treat pain and addiction].”104  
“I am hesitant to use opioids because the patient has a history of alcoholism, uses 
marijuana for pain currently, and has a history of opioid abuse.”119  
Other providers were cautious or hesitant to prescribe opioids for older patients and were 
uncertain in their prescribing abilities for this specific population. They were uncertain with how 
these individuals would respond and felt that the potential harms outweighed the potential 
benefits.  
“I just have a hard time prescribing opioids in my older patients. I get frightened with 
80+ year olds; how are they going to respond?”122  
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Emotion  
Eight studies106,112-114,116,117,122,123 that reported on 188 providers (157 primary care, 19 
nurse practitioners, 1 physician assistant, 10 residents, and 1 other) yielded high confidence that 
concerns over problematic use, addiction, dependence, tolerance, and side effects were barriers 
to prescribing opioid analgesics to manage CNCP. Some providers were concerned that 
increasing opioid doses would contribute to habituation, misuse, or addiction. This resulted in 
reluctance to increase the dose or avoidance of prescribing long-term opioids altogether.  
“I always try to use medications that aren’t addictive first… I try to avoid using narcotics 
long term for that very reason.”114 
“You never get an adequate level of pain control and you keep adding the doses up and 
they get habituated. An end point is very difficult to achieve.”106  
“So what you’re telling me is you need twice as many Percocet as usual because of X, Y, 
Z. I hear you. On the other hand, my training in chronic pain is that this is a very high-
risk thing to do, and I am uncomfortable with that high of a dose.”117 
Some providers feared tapering or discontinuing opioids due to the choices their patients 
might make in response to this. They felt that they needed to continue prescribing opioids in a 
controlled fashion in order to avoid the possibility that patients would resort to alternative drugs 
or illicit opioids. 
“In others, stimulant use and alcohol use goes way up when I titrate down their opioids. 
So, prescribing opioids in a controlled fashion for their pain, despite their pain risk, 
seems to be less risky.” 123  
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“I can see [patients] going out and getting something [opioids] off the street and then 
overdosing because they never have done that before.”116 
Three studies105,114,116 that reported on 38 providers (21 primary care, 3 specialist 
physicians, 13 nurse practitioners, 1 physician assistant) indicated that concern over regulatory 
scrutiny was a barrier to prescribing opioids for CNCP (moderate confidence). Providers have 
expressed concern over the loss of their job or license if they inadvertently harm their patient. 
This concern was inversely related to willingness to prescribe opioids.  
“There’s always a lurking fear… certainly someone could overdose on what I prescribed 
and then their family member could try to press charges… My license is on the line as 
well.”116  
“Every week I deal with somebody, I admit somebody, and literally I have to distrust 
what they tell me because if I write down on the chart and order what they tell me to 
order, I’ll kill them. And doctors have lost their jobs, on my ward, over that issue.”105  
Beliefs About Consequences 
 Four studies104,114,116,118 that reported on 78 providers (50 primary care, 17 nurse 
practitioners, 9 specialist physicians, 2 physician assistants) yielded moderate confidence that 
concern regarding diversion of prescription opioids was a barrier to prescribing for CNCP. Some 
providers felt that they were partly responsible for diversion because they were prescribing 
opioids and were concerned about who was on the receiving end.  
“When I discovered my patient was selling medications… it was a feeling of like, “I am a 
drug dealer, I’ve been a drug dealer for the community for three years.” And that’s a 
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shitty, shitty feeling…. It was the actual reality that like I was contributing to that [drug 
use]…”118  
“God knows where those drugs [prescribed opioids] are going and who is dying from 
those drugs.” 116 
“If you prescribe to a population where you think diversion is going on, you definitely 
have a responsibility. I also worry about who is getting the drug, is it my son? I mean, we 
are members of the society after all.”114 
In some instances, providers immediately ceased prescribing opioids after discovering 
that their patients were contributing to drug diversion.  
“When I found out I was also prescrbing for her sister and her mother I realized that 
single handedly I was probably prescribing for all of New Haven, and immediately got 
them off.”104 
Environmental Context 
Eight studies104,115,117,120,123,127-129 that reported on 188 providers (169 primary care, 9 
specialist physicians, 7 nurse practitioners, and 3 other) yielded high confidence that inadequate 
appointment durations did not allow for a thorough patient assessment which was a barrier to 
prescribing opioids for CNCP.  
Some providers felt that documentation and formal assessments took up a sufficient 
amount of time. Some providers reduced the number of patient encounters or cut corners during 
assessments and documentation because of this.  
“Time. They take up an inordinate amount of time… Trying to address what the pain is 
and the causes for it takes up an inordinate amount of time. Let me show you the 
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paperwork on one, all of the paperwork that had to go into this, the consult and 
everything…This is why you have to limit the number, you can’t see a lot of them because 
there’s so much paperwork.” 104  
“It’s racing from one patient to another, and sitting down and doing formal assessments 
is hard to work in… but formal assessment scales and these lengthy conversations that 
you would think family practitioners would sit down and spend all this time, this practice 
isn’t set up to do that. It’s set up to move 35 000 patient visits through a year.”115 
“… All this stuff that I’m supposed to be doing, taking a complete history, complete 
addiction history… But don’t have time to do what I am supposed to do in terms of 
proper treatment, opioid treatment, so I cut corners a bit.” 127 
Other providers felt that there was insufficient time allocated to provide education about 
pain management, narcotics, or alternative resources.  
“And I think that this is tough in our busy practices, to actually take time to really 
educate people about pain, and that’s why we offer this chronic pain program through 
our family health team… But you can imagine a physician that doesn’t have access to 
that. You don’t generally have the time to spend in sessions talking about how to manage 
pain.”123  
“A major issue that hasn’t been brought up is time and resources. And there’s no way 
you can consistently put 20 pounds of potatoes in a five-pound bag and, you know… I 
think everyone around the table is very conscientious, very aware of the risks. It’s a 
matter of resources, time, that is not allocated, and that’s the nature of medicine today, 
and it’s the nature of primary care.”117 
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“Oh the time to address and withdraw narcotics… It just takes hours.”129 
Data from three studies106,114,122 that reported on 60 providers (48 primary care and 12 
nurse practitioners) yielded high confidence that experiencing patient-related salient events (e.g., 
overdose or death of a patient) lead to providers becoming hesitant to prescribe opioids to 
manage CNCP. These previous experiences made them become more guarded when prescribing 
opioids.  
“It is both your cumulative experience and, sometimes when you’ve had a negative 
experience, it really biases how you think. I’ve had an experience where my patient 
actually overdosed. She crushed up the oxycodone we were giving her in the hospital and 
shot it up through her central line and died. We’ve all had experiences with opioids being 
abused. This just happened to be a very dramatic thing that happened right under my 
nose. It just makes me more guarded, in terms of my practice, and the lengths people will 
go through to do harm to themselves with opioids.”106 
“I had a patient die. He took the entire bottle, and the police came to see me because they 
found him dead with the empty bottle with my name on it, and I say to patients now, ‘I am 
only going to give you a small amount, because I don’t want you found dead with my 
name on your bottle’.”114  
“One of my 96 year-old female patients got an opioid and went to sleep for three days 
after taking it. It really clouded her sensorium, so that was a negative experience for her 
as well as for me.”122 
Data from three studies110,124,129 that reported on 62 providers (50 primary care, 8 nurse 
practitioner, 2 pharmacists, 2 others) yielded high confidence that the experience of healthcare 
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provider-related salient events (e.g., assault or threats to healthcare providers) reduced overall 
willingness to prescribe opioid therapy.  
Some patients would threaten self-harm if opioids were tapered or discontinued.  
“He [the patient] did a lot of getting up and yelling at me, just kind of laying out his 
frustrations and basically saying I’m not caring for him and he’ll end up dying and all 
this and that’s on me.”124  
“One guy I am thinking of said, “When I have this much pain, I feel like killing myself. 
My uncle killed himself because no one treated his pain.” So you get this barrier of 
‘don’t touch it or you might be causing suicide,’ you know, and we are so highly attuned 
to that.”124 
Other patients became physically or verbally violent, or verbally threatened their provider 
after their opioids were tapered or discontinued.  
“When I worked at a hospital I actually had a situation like that where that the man had 
gotten mad and he two weeks later moved into the same community that I lived in… [I 
told] my babysitter to watch for this man.”110  
“I’ve had patients come in and say, ‘I know where you live.’”110  
“… I’ve had someone hit me with their cane. I’ve had my car keyed… I already had 




Facilitators of Opioid Prescribing 
Social Influences 
 Data from 13 studies104,105,107,110-113,115,117,118,122,123,129 that reported on 364 providers (306 
primary care, 12 specialist physicians, 19 nurse practitioners, 10 physician assistants, 2 
pharmacists, 10 residents, and 5 other) yielded moderate confidence in the observation that 
healthcare providers are more willing to prescribe opioids when they have a trusting relationship 
with patients. This trust stems from the amount of years spent with the patient, having open and 
honest discussions about the dangers of opioids, compliance with the prescribed frequency, and 
when behaviours expressed from the patient represented their level of pain.  
“The first thing is obviously I know this patient for, let’s say, several years, and I never 
detected any suspicious specific requests for narcotic pain medications.”113 
“I could trust him because he wasn’t always just increasing it; sometimes he would have 
less, and sometimes he would ask [for] Percocet instead of Vicodin, which generally 
many people find it stronger, and so if the pain was worse and [he would] ask for 
Percocet, and he would in fact ask me to switch him back to the Vicodin at some point, so 
I kind of trusted… that he was getting the medications that he felt he needed at the 
time.”112 
“Her report to me is that the narcotics help and she has not asked for meds easily... She 
has been savvy about her use of the medications, about asking for the narcotics, and so 
I’m not concerned about prescribing for her. I trust her more than some patients.”112 
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“I’ve known some of my patients for over 20 years. Whether it’s right or wrong, I guess I 
have a sense of whether they’re someone that I feel I could or would appropriately use 
these medications.”115 
Some providers recalled times when they were unsure whether they could trust their 
patient. Providers became reluctant to prescribe opioids when they felt that they were being lied 
to or were skeptical of patient motivations, when they thought that patients misrepresented their 
pain, had an ‘addictive personality’, or evidenced history of substance use.  
“We have all had experiences where patients have been misrepresenting their physical 
findings and there’s been a discrepancy between what they report and what we see. And, 
unfortunately, it is a very distrusting relationship inherently.”105 
“Just the being lied to when you really trust a patient and you feel like you’re trying to 
help them.”105  
“I think there is a distrust, or a suspicion, because it is so easy for the patients to put on a 
show, so you don’t really know if the pain is true or false.” 111 
“[I have patients who report that] their back hurts all the time, but then they jump right 
up onto the exam table, I don’t get that.” 122 
“He’s concerned I don’t give him the pain meds; I never quite trusted him, but after the 
positive toxin screens for cocaine and after discovering that he was addicted to heroin, I 
think that was the breaking point... I stopped doing my [iatrogenic] harm from care by 
cutting him off from narcotics. At least I wasn’t contributing to his diversion or his abuse, 
but I haven’t found a way to help him.”112  
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Some providers aimed to treat each new patient individually and ensure that their level of 
trust was case-dependent by avoiding letting previous experiences bias perceptions and attitudes 
toward new patients.  
“… Depends on my comfort level with that patient to begin with, my relationship with 
that patient is probably a direct correlative to my comfort with prescribing other 
medications and controlled substances.”110 
“I really try to look at this as a fresh new patient. They have their own set of 
circumstances and trying to start fresh rather than, ‘this is another drug-seeking patient 
that I have to deal with and another chronic pain patient.’ So trying to go into every 
[visit] with an open mind and trying to give them the benefit of the doubt, because a lot of 
the times we don’t do that, we are just suspicious right off the bat.”111  
Four studies107,108,117,121 that reported on 81 providers (63 primary care, 7 specialist 
physicians, 7 nurse practitioners, 1 physician assistant, and 3 other) provided low confidence that 
risk management tools for opioid prescribing facilitated open communication with patients 
around opioid prescribing.  
“So this section I’ve showed the patients. I’ve also showed the patients changes in dose. 
So you know, ‘You can see how we’ve changed over time.’ So I have done that with them 
to… say, ‘We’ve been stable for a while, then we went up [and] what happened 
here?’”104 
“Sometimes I use it as a strategy, the 200mg of morphine. That’s what I tell the patient: 
‘you’re at a high dose, you’ve gone above the recommended dose, we need to wean you 
off.’”108 
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“It has been helpful to have more people [signing the management plan] once a year. 
Going over stuff with the patients, like, ‘We’re going to review your [pain registry] 
report, we’re going to review your urine toxicology screener’.”107 
Some providers reported that these tools can create tension in the clinical interaction and 
may hinder conversations about opioid misuse.  
“One of the downsides to [management plans]… the conversation [about substance use] 
goes down, it makes it more secretive… In some ways we can’t talk about, ‘Are you 
actively using [illicit drugs or alcohol]?’ as much because [patients] know it’s a 
violation of pain management agreements. So that does limit the way we can talk about it 
substance use.”107  
Goals 
 A sample of 74 providers (64 primary care, 7 nurse practitioners, and 3 other) reported 
that establishing treatment-related goals with patients (e.g., tapering opioids or promoting 
improvement in function) facilitates opioid prescribing (moderate confidence).117,118,126,129  
“Each time I saw him, I would tell him whether I kept the dose the same or decreased it, 
the goal is that by this time, you’re going to be off narcotics, you know, like very 
consistent messaging that this is not going to be a forever thing.”117 
“… the goal is not for his pain to… his pain probably won’t be gone forever. He 
probably won’t have the strength he had in his hands when he was 20 years old either. 
No matter what we do the goal is just to improve as much as we can and have him 
functioning as much as we can.”126 
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“I establish ground rules with them and now I am even saying no early refills even for 
legitimate reasons…”129  
Knowledge of Opioid Prescribing Tools 
Two studies that reported on 20 providers (20 primary care) indicated that training and/or 
education sessions on the use of opioid prescribing tools facilitates opioid prescribing.109,121 
Confidence in this interpretation was rated low due to adequacy of studies and limited breadth of 
providers included.  
“I don’t tend to need to go back and look at all of the various medications for example, 
or which ones I should be starting with, because I’ve become familiar with it. I’m very 
familiar with the overdose risks for example.”121 
Environmental Context 
Twelve studies104,107,117,119,120,123-128,130 that reported on 254 providers (202 primary care, 
9 specialist physicians, 11 nurse practitioners, 3 physician assistants, 25 pharmacists, and 4 
other) yielded moderate confidence that lack of available non-opioid treatments (e.g., substance 
use treatment programs, pain clinics, community resources) promoted the prescription of opioids.  
“Where’s the support? Yeah, but where’s the multidisciplinary approach? There aren’t 
any community resources out there to help us... It takes some time to find a resource, for 
physio or for massage, all those other things that could help manage pain. And it takes 
some time to get those in place. There’s not another great alternative pain-management 
mechanism out there, both pharmacological and even again, non-pharmacological. 
Often, [patients don’t qualify] and they can’t get access to a lot of the other supports.”123  
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“I feel completely unsupported by the substance abuse treatment community. It just 
doesn’t exist. There’s nothing… It has not been developed in such a way to become more 
accessible, to be less stigmatized, to be effective.”107  
“We’ve pretty much tried everything by the time they’re on chronic narcotics… That’s an 
incredibly difficult one because most of the time, I don’t have anything else to offer 
people, especially at [a safety net hospital] where we don’t have behavioural therapy and 
other things… that other places may have.”117  
“She’s stable and is a single mom working and has limited access to adjunctive therapies 
and physical therapies.”128  
“[Chronic narcotic therapy] creates most of our problems in life, in terms of satisfaction 
with how we work, stuff like that. But you really don’t have many other options, 
really.”120  
Four studies reported that reported on 82 providers (67 primary care, 13 nurse 
practitioner, 2 others) felt that institutional pressures acted as a facilitator to the prescription of 
opioids to manage CNCP.106,110,114,128 Coherence between studies was low with some studies 
reporting benefits to institutional pressure, such as institutional protocols offering structure when 
prescribing.  
“… there is a policy… no new patient is going to get a controlled prescription… I tell my 
patient(s) that with our policy, I cannot do anything… There are a lot of benefits to the 
policies and the contracts.”110  
Other studies report detriments from institutional pressure. For example, the 
implementation of protocols promoted quick discharge times, which has pressured providers to 
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prescribe opioids. Institutional pressure from managers resulted in providers feeling pressure to 
prescribe opioids.106,110,114,128  
“If a patient tells you that they are in pain and they are receiving opioids in the hospital, 
and I have a strong sense that this is a person who comes back to the hospital easily and 
regularly if something is not right, I’m more likely to make sure that the patient has 
adequate pain medicine for a reasonable duration of time to reduce the chance that they 
get readmitted just for pain alone.”106  
“I get a call from the case manager who says would you be willing to consider the 
following: would you be willing to consider prescribing her methadone as a pain 
management medication and not as a methadone maintenance for her substance abuse 
disorder… Looking back now it’s one of these… what the heck was I thinking kind of 
thing… I sort of felt like I was getting stiff-armed into things.” 128  
Institutional pressure was graded low confidence due to the low coherence between studies.  
Discussion 
Data was reviewed from 27 qualitative studies reporting on 599 healthcare providers and 
identified empirically supported barriers and facilitators to prescribing opioids for CNCP with no 
judgment made to appropriateness of prescribing. Empirically supported barriers included: 1) 
perceived insufficient education on pain management and opioid prescribing during formal 
education (moderate confidence); 2) low perceived self-efficacy for prescribing opioids for 
CNCP (moderate confidence); 3) concerns over problematic use, addiction, dependence, 
tolerance and side effects (high confidence); 4) concern over diversion of opioids (moderate 
confidence); 5) concern over regulatory scrutiny (moderate confidence); 6) inadequate duration 
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of appointments with patients (high confidence); 7) the experience of patient-related salient 
events (high confidence); and 8) the experience of provider-related salient events (high 
confidence). Empirically-supported facilitators for the prescription of opioids to manage CNCP 
included: 1) presence of a trusting patient-provider working alliance (moderate confidence); 2) 
lack of non-opioid alternatives (moderate confidence); and 3) goal setting with patients 
(moderate confidence). Insufficient evidence was observed to draw confident conclusions about 
the influence of institutional pressure or the use of risk management tools as facilitators of opioid 
prescribing.  
Providers reported concerns over patient adverse effects, physical tolerance, and 
addiction which may represent relative risk-aversion, or an accurate appreciation for potential 
harms. Providers from a qualitative synthesis also expressed the concern of potential misuse and 
addiction when prescribing opioids; however, some providers preferred to risk the potential of 
opioid misuse rather than risk under-treating pain – a finding that is inconsistent with our 
results.91 When measured quantitatively, a large proportion of providers consider potential 
misuse, tolerance, or overdose as barriers to prescribing opioids.53,61,62,71 Chronic opioid use is 
associated with an increase in risk for developing opioid use disorder, overdose and death.131-134 
Given the potential harms associated with opioid use, providers are justified in their concerns 
and uncertainty when prescribing opioids for patients with CNCP. Multidisciplinary treatment 
clinics including substance use treatment approaches have been recommended by guidelines to 
assist patients who present with complex issues. 29,56 Unfortunately, clinics may not be readily 
available for patients, as demand often exceeds availability. Lack of availability may result from 
underfunding of clinics, lack of knowledge or awareness of such pain management clinics, or 
lack of community access to publicly funded allied health practitioners (e.g., psychologist, 
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occupational therapist). 135 Healthcare providers  also lack readily accessible referral pathways. 
As such, formal linkages between providers and treatment clinics are needed to allow for rapid 
access and to provide a wide variety of treatment options for patients.107  
Providers also reported concerns over drug diversion as a barrier to prescribing opioids 
for CNCP. Population-based estimates indicate that the prevalence of diversion within the 
community is 5%136 with rates of diversion increasing as opioid prescribing rates increase.137 
Reasons for opioid diversion vary, ranging from lack of unawareness of the consequences of 
opioid diversion,138 poor education about proper storage and disposal of opioids,139,140 to aberrant 
medication behaviours or misusing opioids.47 A number of interventions have been 
recommended to reduce drug diversion and help identify individuals who are at risk of drug 
diversion, including: Education sessions; urine screening; patient contracts; low dose initiation; 
gradual dose titration; prescription drug monitoring programs; increasing monitoring of patients; 
completing multidimensional assessments with patients before prescribing opioids; and ongoing 
monitoring.141-143 Clinical evidence suggests that it is unclear whether these interventions have a 
direct impact on reducing opioid diversion.141 As such, there is a need to develop empirically- 
and clinically-based interventions to mitigate opioid diversion. In addition to this, policies could 
also be targeted towards focusing attention on the management of the social supply of 
pharmaceutical drugs, which most commonly occurs through friendships or social groups (e.g., 
students in fraternity/sorority environments).47  
Providers reported that negative patient-related salient events (e.g., patients who have 
overdosed)106,114,122,128 and provider-related salient events (e.g., threat to provider)110,124,129 
impacted the delivery of care. Negative events are more salient, potent, and dominant than 
positive events,144 and salient negative events can result in cognitive biases that impact the 
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delivery of medical care.79,80 One such bias is the availability bias which occurs when providers 
recall and use salient past events to influence current decision-making processes.83 Our results 
support the role of this bias as numerous providers recalled previously experienced negative 
salient events and used these events to influence their decision making practices surrounding 
opioid prescribing. Previous research has demonstrated similar findings in line with this, further 
supporting the notion that availability bias can influence clinical decision-making.145 
Experiencing negative salient events is also supported through the representativeness bias which 
involves evaluating a current patient relative to previous similar patients.84 It would appear that 
negative salient events lead to the creation of a mental prototype of patients with CNCP being of 
high potential personal risk, which influences willingness to care for future patients with 
CNCP.114 While biases can often be informative and helpful when making quick clinical 
decisions,80 there may be unintended consequences (e.g., undertreating pain) when providers 
focus specifically on previously experienced negative events. As such, it may be important for 
providers to critically evaluate practice behaviours, and include both successful and unsuccessful 
experiences with opioid prescribing when treating future patients.106 Providers may also benefit 
from learning cognitive behavioural techniques to challenge biases, such as cognitive 
restructuring to acknowledge negative or distorted thoughts and promote reasoned practice.146 
Previous medical centres have incorporated cognitive bias awareness into their curriculum and 
have found promising results, demonstrating that residents were able to recognize biases and 
create strategies to avoid making similar errors in the future. 147-149 It is important to continue to 
reinforce these skills throughout the medical career as these skills can be forgotten if not 
practiced regularly.   
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Sufficient evidence was synthesized in the present review to indicate with moderate 
confidence that concern over regulatory scrutiny was a barrier to prescribing opioids for CNCP. 
Providers endorsed fear of being found liable for patient overdose leading to death which could 
result in the potential loss of professional licensure.105,114,116 Evidence from surveys distributed 
across various providers observed similar results, indicating that fear of being found liable for 
patient death or fear of legal investigation resulted in reluctance to prescribe opioids. 53 78 90 
While regulatory scrutiny and sanction can be effective methods for managing opioid prescribing 
behaviour, regulatory policies vary by province, region, territory, state, and country, and can 
result in barriers to prescribing150 as well as unintended consequences, such as patients not 
receiving necessary prescriptions and seeking illicit opioids.151  
Providers expressed reluctance to prescribe opioids for CNCP due to insufficient formal 
education on opioid prescribing.114,121,125 Canadian medical undergraduate education programs 
offered an average of 16 hours on pain management in 2007,152 and estimates suggest that only 
20% of physicians in the United States have received training about recognizing drug diversion 
or identifying signs of substance use disorders while in medical school.153 Healthcare providers 
also reported a lack of confidence in their abilities to prescribe opioids to manage CNCP, 
specifically when prescribing opioids to patients without a medical explanation for pain106,122 and 
when treating those who have co-morbidities (e.g., substance use disorder or mental 
illness).104,119 Education and training in chronic pain is necessary in order to enhance provider 
knowledge, confidence, and self-efficacy surrounding chronic pain management, opioid 
prescribing, and identifying drug abuse and addiction among people with chronic pain.154,155 
Studies evaluating education interventions have been varied with some,156 but not all157 
interventions demonstrating improvement in knowledge and self-efficacy surrounding chronic 
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pain management and opioid prescribing. Increased awareness of the necessity and importance 
of chronic pain education across North America has led to medical schools implementing various 
chronic pain educational models in their curriculum, such as immersive training modules, 
mandatory seminars, and preclinical conferences to help physicians practice “thoughtful 
prescribing.” 158 While these models are being implemented, the effects of such education 
initiatives have yet to be determined. State Boards of Nursing also provide nurse practitioners 
with resources and information on the mitigation of opioid misuse and diversion, in addition to 
information pertaining to continuing education.159 While the majority of state websites provided 
at least some information on the mitigation of opioid misuse and diversion, 35% of websites 
included little to no information on this topic. Further, only 43% of websites provided 
information for continuing education links and 15% provided information on mandatory 
education. Finally, the majority of websites were difficult to navigate, making it hard to retrieve 
necessary information pertaining to continuing education, drug misuse, and diversion for opioids. 
Websites could be improved to ensure easy navigation and easy access of information to assist 
nurses when dealing with opioids for people with chronic pain.159  
Consistent with the notion that brief medical appointments are considered a barrier to 
managing patients with chronic disease in primary care,160-162 providers felt challenged to 
adequately assess, monitor, and weigh the risks and benefits of chronic opioid therapy with 
patients during brief appointments in primary care.104,123,127 The management of chronic diseases 
often require more time than physicians have available, which is a significant obstacle to the 
delivery of quality care.161 This is interesting given that a recent cross-sectional study of 
physician behaviour in primary care reported that opioid prescriptions increase by 33% as the 
workday progressed and by 17% when appointments ran behind schedule.163 It would appear that 
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brief appointments in combination with a perceived lack of availability to discuss non-opioid 
therapies, influences clinical decision making when prescribing opioids. A significant proportion 
of providers felt that there were little to no alternative therapies available to assist patients. Those 
who were aware of potential alternatives felt challenged to discuss non-pharmacological options 
during short appointment durations.120 In support of this, a perceived lack of non-opioid 
therapies was identified as a facilitator for prescribing opioids.117,120 Canadian guidelines for 
opioid therapy in chronic non-cancer pain highly recommend maximizing the use of non-opioid 
therapies.56 Yet, access to such therapies are difficult due to long wait list times,164 few 
multidisciplinary support programs available,165 and lack of access to publicly funded allied 
health professionals (e.g., physiotherapy, psychology).135 Evidently, there is a need to initiate 
financial incentives to accommodate for prolonged visits, to improve availability of non-opioid 
pain management approaches to better align opioid prescribing practices with practice 
guidelines, and to connect patients with the appropriate resources necessary.166 One potential 
solution is for policy makers and insurance companies to ensure access and coverage is available 
for various non-opioid alternatives, and to allocate resources to support these models.117  
The patient-provider working alliance was a robust facilitator of opioid prescribing and 
appeared to center around trust and safety. Providers reported that patient withholding or 
minimization of information (e.g., history of substance use) reduced willingness to 
prescribe,105,107,111 while open communication and a trusting relationship facilitated opioid 
prescribing.110,112 Providers reported using risk management tools, treatment goal setting, and 
shared decision-making to facilitate open communication with patients. Unfortunately, 
confidence in using opioid risk management tools may be misplaced given that there is not a 
rigorous body of evidence supporting their use. Canadian physicians raised concerns about the 
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2017 Canadian Opioid Guideline56 for CNCP’s lack of recommendation for opioid prescribing 
screening tools to help inform decision-making, as it was previously mentioned in the 2010 
guideline. The more recent guideline made no such recommendations because there is no 
empirical evidence supporting the validity of opioid prescribing screening tools.167 Preliminary 
evidence suggested that factors adding complexity or uncertainty (e.g., mental-health history, 
comorbidity) influence clinical decision-making surrounding opioid analgesics.119 Longstanding 
patient-provider relationships and shared decision-making can reduce the impact of this 
complexity. Research suggests that physicians demonstrating compassion, having a strong 
working alliance, and portraying a patient-centered approach that involves patients in treatment 
decision-making have been shown to improve provider clinical decision-making, positive 
communication, patient health, and treatment adherence.168,169 As such, it may be of benefit to 
provide physicians with training programs to improve or enhance working alliance skills with 
patients.169 This may help to reduce various relational difficulties that can be found when 
working with patients who have CNCP.170 
The provision of education about opioid prescribing and chronic pain management have 
been proposed as a method for mitigating the opioid crisis.171,172 Enhanced education initiatives 
have been driven at the state, provincial, and federal levels. For example, Health Canada has 
committed more than $2 million CAD for the development of a curriculum in chronic pain 
management at the medical undergraduate level. While necessary, knowledge tends to be 
insufficient to promote behaviour change. Clinical practice guidelines have been published to 
assist in the judicious prescription of opioids for CNCP;29,56,66,67 however, provider uptake of 
such knowledge is less than optimal despite awareness of guidelines.57 Interventions that focus 
primarily on education only address one influence of the complex clinical decision-making 
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algorithm involved in the prescription of opioids for CNCP. Behaviour change techniques (e.g., 
as summarized in the behaviour change technique taxonomy173) based on established theories of 
behaviour change (e.g., self-determination theory174) that map onto the TDF101 may be required 
to address the barriers identified in this review. In addition to education to address gaps in 
knowledge,171 such interventions could include: 1) motivational communication to address issues 
pertaining to motivation and self-efficacy; 175,176 2) training in communication and shared 
decision-making to improve the patient-provider relationship;177,178 3) connecting primary care 
providers with specialist physicians through programs such as “Project Extension of Community 
Health Outcomes Chronic Pain and Opioid Stewardship” or mentorship networks such as the 
“Atlantic Mentorship Network – Pain & Addictions”;179 4) cognitive behavioural approaches to 
circumvent cognitive biases that may undermine the timely delivery or intensification of 
treatment (e.g., overestimation of provider’s “gut-level” assessment of risk); and 5) improving 
availability and access to non-opioid pain management interventions. Two recent trials have 
provided encouraging evidence to indicate that multifaceted interventions can be developed and 
tailored to the local context in order to improve provider uptake of recommendations endorsed 
by opioid prescribing guidelines.180,181 
Limitations of the Literature 
There are some considerations that limit the strength of conclusions drawn from this 
review. Primarily, almost two thirds of providers in the review consisted of general practitioners 
and only 3% were specialists. Although general practitioners account for the majority of 
prescribers, this did not allow us to capture the entire range of providers who prescribe opioids 
and can limit generalizability if the aim is to extrapolate to specialist providers. Additionally, 
sufficient evidence was available to understand the individual contribution of  barriers and 
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facilitators, but we were unable to assess the cumulative and complex interactions between 
influences. Future research is needed to elucidate complex relationships and move towards a 
multivariate understanding anchored in a framework of behaviour change (e.g., theoretical 
domains framework65), or models of behaviour change, such as theory of planned behaviour182 or 
self-determination theory.174 Such an understanding will better elucidate influences of behaviour 
change, improve hypotheses regarding mechanisms of behaviour change, and inform tailored 
interventions. 
Limitations of the Review 
 First, we focused on evidence from North America. Given the socio-political nature of 
the opioid crisis, the results of this synthesis may not extend to other geographic regions. Second, 
studies that focused on opioid use disorder, and the prescription of opioid agonist and antagonist 
treatments were excluded. Results may not generalize to the prescription of opioid agonist 
treatments which are included in recent clinical practice guidelines. Third, this is the first time 
using the TDF model to identify behaviours of prescribing practices. As such, some prescribing 
behaviours did not directly match up to behaviours identified in the TDF model (e.g., patient-
provider relationships). Alternative coding for the framework could be used to better align with 
provider prescribing practices. Nevertheless, the TDF model is empirically supported, along with 
the CASP and CERQual ratings, which strengthen the results of the review. Fourth, publications 
in the review range from 2007-2019 and the results have been amalgamated. Given that 
prescription opioid rates have plateaued around 2011, this may have an effect on results 
identified in the review. Despite this concern, over half of publications in the review including 
more than two thirds of the sample size have been published within the last three years, 
highlighting the recency of the review and potential accuracy of provider beliefs. Finally, the 
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focus of this review pertained to prescribing opioids rather than the appropriateness of opioid 
prescribing (i.e., alignment of prescribing with clinical practice guidelines) due to the limited 
literature available on appropriate prescribing. As such, some facilitators to prescribing may 
represent barriers to appropriate prescribing. For example, a lack of opioid alternatives facilitates 
opioid prescribing, yet can be considered a barrier to the appropriate prescription of opioids for 
individuals with CNCP. 
Conclusion 
 Healthcare providers have an ethical responsibility to work with patients to manage 
CNCP, and such management may include chronic opioid therapy. Several patient-related (i.e., 
concern over adverse effects, tolerance, and addiction), provider-related (i.e., knowledge, self-
efficacy, concern over regulatory scrutiny), and environmental (i.e., salient events, inadequate 
duration of appointments) barriers to prescribing opioids for CNCP were identified, whereas 
facilitators pertained primarily to the patient-provider relationship and insufficient availability of 
non-opioid alternatives. Solutions may involve additional education, mentoring or support from 
experts, ensuring that regulators apply appropriate scrutiny consistent with best evidence, 
guidance for providers on how to best interact with challenging patients, improving accessibility 
to non-opioid treatments for CNCP, and ensuring that providers understand the established risk 
factors for various adverse events. The use of patient decision-aids for opioid prescribing may 
ensure better concordance between prescribing decisions and patient’s values and preferences, 
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Flow Diagram Depicting Article Inclusion and Exclusion Along with Reasons 
Qualitative studies 
 (n=27 citations reporting on 26 
studies) 
Records identified through database 
searching 










Additional records identified through 
other sources 
(n = 1) 
Records after duplicates removed 
(n = 10,707) 
Records screened 
(n = 10,707) 
Records excluded 
(n = 10,324) 
Wrong outcome (n=4,184) 
No original data (n=2,741) 
Outside NA (n=1,146) 
Not chronic pain (n=939) 
Focus on cancer (n=929) 
Conference abstract (n=385) 
Cohen’s Κ = (0.92) 
95.98% agreement 
Full-text articles assessed 
for eligibility 
(n = 383) 
Full-text articles excluded 
(n = 266) 
Includes acute pain (n=68) 
Includes cancer pain (n=49) 
Outside NA (n=22) 
Focus on OUD (n=24) 
No provider-factors (n=48) 
No or insufficient data (n=18) 
Opioid prescribing was not a 
focus (n=20) 
Included non-HCPs (n=15) 
Included children (n=2) 
 
Cohen’s K = (0.62) 
80.78% agreement 
Studies included in full 
knowledge synthesis 























NA = North America 
OUD = Opioid Use Disorder 

























(n=2), FM (n=1), 


























(1) Physician factors: lack of expertise in 
treating pain with or without opioid 
addiction and/or co-existing disorders; 
interest in pain management, aberrant 
behaviours in patients, frustration of 
prescribing opioid analgesics, benefits of 
opioid agreements and continuity of care. 
(2) Patient factors: physician responsiveness 
to patients' pain, fear of addiction, concern 
about cost of specialty pain management, 
patient motivation. 
(3) Logistical factors: barriers of pain 
management referrals, addiction referrals, 
diagnostic workup, ancillary staff, time, and 
insurance coverage 
 
To incorporate interventions into medical 
education to improve provider knowledge and 










adults with CNCP 

















(1) Little trust in the patient due to previous 
lies. 
(2) Complicated clinical patient-practitioner 
relationships. 
To have physicians adopt the role of epistemic 
humility in order to demonstrate 















































(1) Low confidence in prescribing opioids 
for CNCP and perceived limited success of 
managing CNCP with opioids. 
(2) Opioid prescribing shaped by personal 
experiences due to limited training. Adverse 
experiences (e.g., patient overdose or 
suspected diversion) resulted in conservative 
prescribing. 
(3) Opioids can improve unmanaged pain 
and prevent extended hospitalization, thus 
improving hospital efficiency. 
(1) Management strategies (i.e., CPG-based 
opioid dose adjustments) are needed; 
involving the patient in the decision to 
temporarily increase their opioid dose may 
improve patient perceived pain control; close 
communication between the hospitalist and 
GP can help with uncertainty. 
(2) Focusing on successful rather than 
negative opioid prescribing outcomes may 
lead to less restrictive and more thoughtful 
prescribing practices; standardizing opioid 
prescribing to protect physicians from 
medico-legal consequences could lessen fears 
about prescribing. 
(3) A delicate balance between the potential 
benefits and drawback of using opioids may 
improve efficiency 
 
Overall implication: The development of 
evidence based strategies to promote optimal 
opioid prescribing for the management of 
acute exacerbations of chronic pain among 
hospitalized patients may benefit both hospital 
providers and patients who have a mutual goal 





GP (n=18); NP 















(1) Benefits and consequences of guidelines 
on the clinician-patient relationship (i.e., 
increase honest communication when used as 
a tool, but can reduce trust when the focus is 
on risk management strategies) 
(1) Educate about use of treatment agreements 
and urine tests to facilitate open conversations 













Constructs Themes Relating to Opioid Prescribing Author Implications 
 
Incentive: $50 gift 
card 
recommendations 






(2) Provider concern about lack of substance 
use treatment plans available for patients  
(2) Sustainable, formal and long-term 
alliances between primary care settings and 

































(1) Positive attitudes but limited use of CPG. 
(2) Contrasting views about the 200mg 
watchful dose. 
(3) Inconsistencies in recommendations: 
Intervals of urine drug screening and pain 
severity-specific recommendations 
(4) Format: Guideline needs to be more user-
friendly. 
(5) Need to improve awareness and use of 
CPG. 
 
Future iterations may wish to reconsider: to 
validate or revise the 200mg/d watchful dose; 
more details regarding urine drug screening; 











provider views of 















(1) The need for a physician CPG took kit 
with information on opioid prescribing. 
(2) Change in the way patients obtain 
monthly medications. 
(3) Improvement in patient self-management 
education and increased access to both 
providers and alternative interventions. 
(4) The importance of a nurse care manager 
to collaborate with providers and patients. 
Further development of a “Chronic Care 
Model” may be a useful way to improve both 
provider and patient challenges in achieving 


























factors lead to 
prescribing 
controlled drugs 
for CNCP through 


















(1) Prescriptions have reduced since 1990s. 
(2) Comfort with patient, truthfulness, pain 
contracts, access to alternative therapies and 
personal safety concerns influence 
prescribing. 
(3) Lack of PDMP integration in electronic 
record is a barrier to use. 
(4) Concern of prescribing controlled drugs 
to women of childbearing age 
Recommendation pertaining to theme 4: 
Prescribers should assess the possibility of 
pregnancy and discuss a birth control plan 
before initiating opioid therapy. The risk of 
pregnancy should be assessed at each visit and 




























(1) Fear of negative patient consequences 
stemming from physicians prescribing 
opioids 
(2) Provider’s self-efficacy towards 
prescribing and patient-provider 
relationships play a role in physician’s 
beliefs about their practicing capabilities 
(3) Behavioural regulation strategies to 
monitor opioid prescribing: providers report 
a lack of available non-opioid alternative 
resources  
(4) Professional role and identity while 
prescribing opioids: Struggle to balance the 
need to treat pain with potential harms 
associated with over-prescribing opioids.  
a) Nonpharmacological interventions that 
connect patients in need with the support that 
may benefit them is warranted; 
b) There is a need for interventions that 
develop capacity amongst health professionals 
to communicate effectively about opioids with 
patients and other professionals. 
c) Solution-based strategies to support 
improved prescribing and management of 
opioids is needed (and can be used by moving 























differences in pain 
management 
among adults with 
CNCP who are 
and are not 














with opioids;  
 
(1) Skepticism of patient motives was 
primary barrier to prescribing opioids. 
(2) Lack of communication between 
providers among patient prescribed opioids. 
(3) Implementation of risk management 
strategies endorsed by CPGs were identified 
as a means of improving patient care.  
 
Coordination and integration of care, clinical 
decision support tools, patient self-
management and quality of improvement are 





























(1) Belief that opioids offer superficial band-
aid for a wound or stepping stone to 
addiction. 
(2) Stigma about prescribing opioids for 
CNCP due to concerns of patient addiction 
and poor evidence for effectiveness on pain 
or function. 
(3) Opioid therapy can raise questions over 
validity of pain and become a source of 
conflict and mistrust that adversely impacts 
the patient-provider relationship. 
 
a) A deeper understanding of the patient’s 
complex lives may lessen physician views on 
drug-seeking behaviour. 
b) Interventions for providers and patients are 
needed to protect the doctor-patient 
relationship. 
c) Patient and provider may benefit from 
chronic pain management models to improve 
communication and shared decision-making. 
d) Physicians should use goal directed care 








Assess effect of 
patient requests 
for specific opioid 
pain medication 












(1) Look for truthfulness across patient 
presentation (e.g., symptoms, demeanor, 
employment) to evaluate authenticity of 
complaint. 
a) The use of initial therapy and testing to 
determine the severity of the pain complaint 
and the risk of drug seeking is worth 






















(2) Importance of knowing the patient and 
their history when deciding authenticity of 
complaint. 
(3) Weighing the risks of under-treating pain 
and medication abuse. 
 
b) Need for valid instruments that can be used 
in primary care settings assess drug seeking 
behaviour. 
 





























for patients  
 
(1) In order of importance, NPs relied on 
etiology of pain, personal experience (i.e., 
biases), and formal education when 
prescribing opioids. 
(2) Perceived inadequacy of formal 
education on opioid prescribing. 
(3) Adverse events (e.g., overdose or death) 
result in reluctance to prescribe and 
perceived need to protect oneself by acting in 
the best interest of NPs. 
(3) Responsible to protect society from drug 


























(1) Importance of objective and consistent 
information about pain. 
(2) Importance of identifying "red flags" 
(e.g., history of abuse, reluctance to try non-
opioid therapies). 
There is potential value to EMR-based 
decision support to ensure physicians are able 
to diagnose pain conditions, weigh opioid 
risks and benefits and judge patient 













Constructs Themes Relating to Opioid Prescribing Author Implications 
Incentive: None analytic 
approach 
 (3) Setting goals and expectations around 
patient functional outcomes can improve 
confidence in prescribing.  
(4) Longstanding relationships increase trust 
and willingness to prescribe. 
(5) Difficulty weighing benefits against risks 
with greatest weight given to potential abuse. 
(6) Time and resource constraints impede 
appropriate prescribing. 
(7) PCPs often “specialize” in chronic pain 
or avoid these patients. 
 
education and policies that support high 































(1) Challenges of pain management using 
opioid analgesics (objective assessments, 
changing guidelines, and lack of coordinated 
approach) 
(2) Patient attachment to opioids that impact 
patient-provider communication (e.g., threats 
that patients will turn to elicit sources, 
patient perception of entitlement to receive 
opioid medications, and patient perception of 
abandonment when tapering). 
(3) Provider frustration related to opioid 
prescribing (e.g., confrontation in clinic 
visits; lack of patient engagement in mental 
healthcare; and complex social 
circumstances including poverty). 
Interventions (such as the CSRG) should be 
implemented to assist PCP prescribing, as 
these interventions may to help reduce stress, 













Constructs Themes Relating to Opioid Prescribing Author Implications 
(4) The role of the Controlled Substance 
Review Group (CSRG; communication 
techniques; supporting mental health 





GP (n=18), NP 
(n=4), PA (n=1) 
 
Incentive: $50 gift 
card 
Understand 
perceptions of risk 















(1) Sense of personal responsibility over 
patient adverse events results in conservative 
prescribing. 
(2) Conservative prescribing due to fear of 
diversion and risk of overdose in the 
community. 
(3) Fear of liability and censure affects 
prescribing behaviour.  
(4) Contrasting views on co-prescribing 
naloxone (i.e., acknowledge and shift risk to 
patient, but is this ethical?) 
 
a) Discuss the risks of opioid therapy and 
explore patients' understanding of those risks 
to improve safety. 
b) Be mindful that opioid monitoring policies 
can stigmatize the patient, and may harm the 
patient-clinician relationship. 
c) Benefit to incorporating information on 
addiction, physical dependence, and overdose 













the opioid crisis 
and the possibility 













(1) Challenges that lead to care deficiencies 
(lack of provider education and alternative 
treatments). 
(2) Using tools (drug screening, use of 
PDMP, obtaining patient history) to mitigate 
opioid abuse and diversion. 
(3) Increased need for interprofessional 
communication and support. 
a) To improve provider education on non-
opioid alternatives;  
b) To improve the ease of use of PDMPs  
c) To implement pharmacist-physician 


















GP (n=34), NP 





























(1) Patient preference and evidence of risk 
behaviours or adverse events can be used to 
identify candidates for opioid tapering. 
(2) Barriers to opioid tapering include: 
emotional burden on providers, poor patient-
provider trust, and inadequate training, time 
and resources. 
(3) Facilitators of opioid tapering include: 
accurate empathy, individualized plan, and 
guidelines/policies. 
a) Interventions to improve opioid tapering 
may include: implement routine screening for 
patient readiness to taper; support providers to 
reduce burnout; develop models for team-
based care during opioid tapering. 
b) There is a need for patient-centered 
educational resources to guide discussions on 
tapering. 
c) Ensure local policies promote access to a 






GP (n=18), NP 


























(1) Encouragement to be responsive to 
patient pain, aggressive marketing, and lack 
of alternative pain management options 
contributed to historic increase in opioids. 
(2) Concerns over safety of opioids and lack 
of evidence about efficacy have contributed 
to pharmacovigilance. 
(3) Acknowledgment that clinicians bear 
some responsibility in opioid epidemic. 
Frustration between balancing concern over 
health effects of withdrawing from opioids 
and health effects of continuing to prescribe. 
 
a) Presenting opioid prescribing in socio-
historical context in formal pain education 
would be beneficial.  
b) Address the challenges of clinical 
uncertainty in opioid prescribing. 
c) Provide students and clinicians with 
opportunities to problem solve opioid-related 

























between PCPs and 
specialists 
regarding patients 














(1) Hesitation to prescribe opioids in patients 
with mental illnesses. 
(2) Advice sought about treatment strategies 
and community resources. 
(3) Responses provided by specialists to 
PCPs, including empathy and support. 
(4) PCPs sought advice regarding safe 
prescribing, deprescribing, opioid rotation, 






























(1) Patient factors that influence prescribing 
(e.g., inappropriate use of opioid 
medications, resistance to non-opioid 
alternatives, patient condition, patient goals, 
therapeutic history). 
(2) Social and environmental factors that 
influence prescribing (e.g., insurance 
regulations, new clinical practice guidelines, 
unmet social needs). 
(3) Clinician characteristics that influence 
prescribing (experience and training; 
perception of their role; interpretation of 
regulations and guidelines; knowledge of 
resources available). 
 
1) Future interventions that are put in place to 
support PCPs in chronic pain management 
should consider the complexity, ambiguity 
and uncertainty associated with pain 
management. They should focus on 
supporting sensemaking, such as aiding 
clinicians in identifying appropriate anchors in 










































(1) Alternatives to opioids are limited and 
difficult to access making opioids viable. 
(2) Patient belief in effectiveness of opioids 
and unwillingness to engage in lifestyle-
management were barriers to tapering. 
(3) Acupuncture/Chiropractor can augment 
opioid therapy. 
(4) Available resources, visit duration, and 
patient expectations about costs and benefits 











To understand the 
impact of a point-
























(1) Use of tool improves education. 
(2) Lack of knowledge, discomfort, concern 
over regulatory sanction, and perceived poor 
“standards of care” were identified as 
challenges to CNCP management, including 
with opioids. 
(3) Tool can improve communication when 
information is shared with patients and other 
healthcare providers. 
(4) Tool can reduce concern over regulatory 

























that contribute to 
time scarcity and 
its effects on 
quality of care 
when prescribing 












(1) Clinician perceptions of pain as a time 
drain. 
(2) Insurance, inherited patients, and the 15-
minute visit: Chronic pain management 
draws attention away from other patients. 
(1) Tools and policies that facilitate the 
assessment and treatment of pain and 
management of opioids need to be tailored to 
reduce the time pressure providers feel when 
prescribing opioids. This can result in more 
effective management of CNCP; 
 (2) Payment models that reimburse for the 
time necessary for CNCP assessment would 
help to alleviate time pressure as a barrier to 
























fear for patients  
 
(1) Opioids not considered first line 
treatment and used with hesitation. 
(2) Provider barriers include fear of adverse 
effects and addiction; insufficient education; 
fear of regulatory sanction; and inability to 
determine organic cause. 
(3) Provider facilitators include studies 
demonstrating safety; patient and family 
education of risks; peer or specialist 
consultation; tools to assist with prescribing. 
(4) Expressed frustration with pressure to 
treat pain. 
 
Collect data to develop evidence-based CPGs 
and algorithms for opioid prescribing later in 
life. This could improve provider confidence 








that inform the 










(1) Clinicians feel frustration and pressured 
to manage inappropriate amounts of opioids 
when inheriting patients on high doses. 
New interventions must be developed to help 
PCPs overcome barriers (e.g., 
contraindications to nonopioid treatment 
alternatives, lack of access to adjunctive 













Constructs Themes Relating to Opioid Prescribing Author Implications 







(2) Co-occurring health problems in the 
patient causes concern for prescribing 
opioids. 
(3) Benefits of opioids for CNCP 
management: chronic opioids are necessary 
to sustain functionality and help manage 
diseases. 
(4) Clinicians experience many challenges 
with weaning opioids including lack of time 
to properly wean opioids and justifying 
tapering when patients are stable at high 
doses. 
 
difficulty of weaning) that prevent the 










Incentive: None  
To learn about the 
methods PCPs 
used to address 
prescription 












(1) Barriers to minimizing the risk of opioid 
prescribing and potential opioid-related harm 
including, resource constraints, and 
geographic constraints (i.e. travel time). 
(2) Strategies clinicians used to address 
common problems when caring for patients 
on chronic opioid therapy (e.g., ordering 
urine drug tests before appointments, referral 
to an integrated pain clinic).  
a) An increase in the use of tele-medicine 
would improve access to pain treatment for 
individuals in remote areas; 
 b) Future research should focus on accessible 
treatments for patients on chronic opioid 
therapy who show signs of substance misuse.  
 c) Future research should design accessible 
and acceptable interventions for overcoming 
patient reluctance to receive 




















(1) Difficult conversations between patients 
and providers impact opioid prescribing 
behaviours (e.g., objections to opioid 
weaning). 
(1) Providers would benefit from additional 
guidance and support regarding how to 






















(2) Clinicians experience ambivalence about 
enacting guideline-recommended changes  
(2) Providers would benefit from support as 
they transition to new standards of opioid 
care;  
(3) Expanding access to resources could help 
reduce provider ambivalence about 
prescription opioid dose reduction or 
discontinuation and bolster guideline-
recommended pain care practices. 
Note: CNCP = Chronic Non-Cancer Pain; COT = Chronic Opioid Therapy; CPG = Clinical Practice Guideline; ED = Emergency Department; EMR = 
Emergency Medical Record; FM = Family Medicine; GP = General Practitioner; LPN = Licensed Practical Nurse; NP = Nurse Practitioner; PDMP = 
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Confidence in the Evidence from Reviews of Qualitative Research (CERQual) Rating of Qualitative Studies 
 
Summary of review finding Studies 
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Barriers:        
Knowledge        
While some reported using knowledge from 
formal education to make clinical decisions 
regarding opioids, most providers felt their 
formal education was insufficient to properly 
prescribe opioids to patients with CNCP. The 
use of opioid management tools and 










(1 serious, 1 
moderate, 3 
minor, 2 none) 
Moderate concerns about 
coherence 
(Some concerns about 
the fit between the data 
from the primary studies 
and the review finding) 
Minor concerns 
about relevance 
(3 thin and 4 


















Beliefs about Capabilities        
Most providers endorsed a lack of confidence 
in prescribing opioids for patients with CNCP, 
both with and without comorbid conditions. 
Reasons for lack of confidence include, 1) 
lack of biomedical explanations for pain; 2) 
lack of guidelines; 3) problem patients; 4) 
older age of patients; and 5) uncertainty of 








(1 serious, 1 mod, 
1 minor-mod, 1 
minor, 5 none) 
Minor concerns about 
coherence 
(Some concerns about 
the fit between the data 
from the primary studies 




















about each facet 
        
 70 
Summary of review finding Studies 
contributing 
to the theme 
Methodological 
limitations 







Beliefs about Consequences 
Providers reported concern over inadvertently 
increasing the risk of opioid addiction among 
community members due to opioid diversion. 
Taking patients off opioid medication and the 
implementation of opioid policies and 
procedures by institutions were seen as a 







(2 minor, 2 none) 
No or very minor 
concerns about 
coherence 
No or very 
minor concerns 
about adequacy 
(3 rich, 1 thin; 8 
different types 
of practitioners) 





because of 8 
different types 









Environmental Context        
Providers found it difficult to appropriately 
assess and manage pain with opioids within 
the duration of a typical appointment. Some 
providers reported reducing client load or the 










(7 none, 1 
serious) 
No or very minor 
concerns regarding 
coherence 
No or very 
minor concerns 
about adequacy 
(6 rich, 2 thin,) 












Providers reported experiencing negative 
events (e.g., death of a patient,) after 
providing opioids to their patients. These 
experiences influenced future prescribing 








(1 moderate, 2 
minor) 
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Providers reported experiencing negative 
patient-related events (e.g., threats of violence, 
physical assault) after providing opioids to 
their patients. These threats lead to provider 
hesitancy to prescribe opioids in order to 
protect their own safety. 




none, 1 serious)  
 


















Emotion        
Providers reported concern about the risk of 
inadvertently contributing to the development 
of patient addiction and/or dependence if they 
prescribe opioids. Fear of opioid addiction 










(2 moderate,  
1 minor-
moderate, 4 
minor, 1 none) 
No or very minor 
concerns about 
coherenec 
No or very 
minor concerns 
about adquacy 

















Providers expressed concern over regulatory 
investigation and loss of their job as a licensed 
practitioner if the prescription of opioids 
inadvertently harmed patients. This concern 
was inversely associated with willingness to 









minor and 2 none) 
No or very minor 
concerns about 
coherence 
No or very 
minor concerns 
about adequacy 
(only 3 articles 
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Facilitators:        
Knowledge        
Educational sessions and/or training in the use 
of opioid prescribing tools were recommended 






(1 serious and  
1 none) 






(2 studies, one 
with thin data 

















Goals        
Providers reported benefit from setting opioid-
treatment goals with patients. These goals 
included tapering opioids or incorporating 
non-opioid treatments into pain management. 




none, 1 minor) 
Minor concerns about 
coherence 
(2 talking about goals of 
tapering with patient, 1 

























Environmental Context        
Most providers reported insufficient 
availability of opioid-alternative pain 
management resources for their patients. 
Some providers utilized specialists for further 
resources. Others reported a lack of qualified 








Minor concerns about 
coherence 
(all talking about limited 
alternative resources – 




(8 rich, 4 thin; 9 
different types 
of practitioners) 
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Insufficient alternative resources were 
positively associated with opioid prescribing. 
(4 serious, 1 
minor-moderate, 
1 minor, 6 none) 
talking about avaliable 
resources, some talking 
about lack of knowledge 




Some providers reported institution pressure 
to facilitate patient discharges through the 
prescription of opioids. Some providers 
reported that institution protocols surrounding 
opioid prescribing helped prescribing 
practices; however, others felt that protocols 












(these articles talk about 
insitutional pressure but 
in different ways: some 
pressure inhibits 
appropriate prescribing; 




(3 rich, 1 thin; 5 
PCP specialties) 

















Social Influences        
Providers prefer to have a healthy, trusting 
relationship with their patients and are more 
willing to prescribe opioids in such cases. 
Patient dishonesty and withholding of 
information is associated with distrust, 
suspicion, and a resistance to start or continue 
prescribing opioids. Some providers reported 
that sharing risks with patients and 
implementing treatment agreement plans 
improved the working-alliance and trust; 
however, others reported that patients will 










(7 none,  
2 minor,  
2 moderate,  
2 serious) 
 
No or very minor 
concerns about 
coherence 
(some concerns about the 
fit between the data from 
primary studies and the 
review finding) 
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Providers reported benefit in open 
conversations with patients about opioids. 
Most providers mentioned that risk 
management tools facilitate communication 
and shared decision-making; however, some 
providers felt that risk management tools will 
result in selective patient-reporting about 







1 mild and  
2 none) 






(3 studies that 
gave rich data, 1 
study that gave 
thin data) 
Minor 
concerns about 
relevance 
(5 PCP 
specialties; 
majority are 
GPs) 
Low 
confidence 
Moderate 
concerns about 
methodological 
limitations and 
coherence 
 
 
